First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research

Over 80 percent of non-small cell lung cancer detected at Stage 4Fewer than 50 percent of patients had five or more biomarker testsMedian time from diagnosis to first-line therapy is about five weeks
Source: McKesson News - Category: Information Technology Source Type: news